Long-Term Follow-up of Subjects Who Were Treated With ST-920

Enrolling by invitation

Conditions studied: Fabry Disease, Fabry Disease, Cardiac Variant

In brief

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Key facts

Study ID

NCT05039866

Run by

Sangamo Therapeutics

People needed

48

Starts

2021-08-16

Expected to finish

2039-03-01

Last updated by the study team

2025-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who received ST-920 therapy in a separate parent trial
• Subjects who have consented to participate in this LTFU study.

You may not qualify if…

• This study has no exclusion criteria

Where it is running

• University of California, Irvine — Irvine, California, United States
• University of South Florida — Tampa, Florida, United States
• Emory University School of Medicine — Atlanta, Georgia, United States
• University of Iowa Hospital and Clinics — Iowa City, Iowa, United States
• University of Minnesota Medical Center — Minneapolis, Minnesota, United States
• Mt. Sinai Hospital — New York, New York, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) — Fairfax, Virginia, United States
• The Royal Melbourne Hospital — Parkville, Victoria, Australia
• M.A.G.I.C. Clinic Ltd. — Calgary, Alberta, Canada
• University Hospital of Würzburg — Würzburg, Germany
• Addenbrooke's Hospital — Cambridge, United Kingdom
• Royal Free Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.